Learning Center
Plans & pricing Sign in
Sign Out



Glaucoma 360
The Cure, The Catalysts, The Care

February 2-4, 2012
The Palace Hotel, San Francisco, California

February 2: The Annual Benefit: Catalyst for a Cure
February 3: Introducing a Forum for New Ideas: New Horizons
February 4: The 16th annual meeting of the Glaucoma Symposium CME

    1. What is Glaucoma 360?

Glaucoma 360 (G360) is a three-day series of events February 2-4, 2012 making possible an extraordinary full-compass
view of The Cure, The Catalysts and The Care in glaucoma today. G360 kicks off Thursday with GRF’s annual benefit;
followed on Friday with the inauguration of a forum for new ideas; wrapping up on Saturday with a Continuing Medical
Education event. This historic confluence of those affected by the disease with top tier glaucoma leaders from the fields
of medicine, science, business, investment, philanthropy and media promises to rivet national and international
attention on challenges and opportunities for treatment and care in the disease, and the leadership role of GRF in
fostering innovative research accelerating the pace of discovery. All proceeds from Glaucoma 360 benefit Glaucoma
Research Foundation for use in its grant-making and other operational priorities.

    2. What makes these events so unique?

The New Horizons Forum is the first of its kind focusing specifically on glaucoma. It brings together experts from clinical
care, research, pharmaceutical and medical device enterprise, investors, venture capital firms, and start-ups – all intent
on transforming new ideas into ways to beat the threat of blindness from glaucoma. The program will provide inside
access to the latest thinking from the most respected investors and leading companies, the newest ideas from some of
the nation’s most promising physicians and scientists, and offer opportunities to network with key opinion leaders
driving the future of glaucoma care. Having the three events: the benefit, the Forum and the CME enables a unique way,
over three days, for those most concerned in finding a cure for glaucoma to share ideas and network.

    3. Why is this so important?

Globally, Glaucoma is the leading cause of preventable blindness. Everyone is vulnerable, from infants to adults.
Anyone over 60, African-Americans, and Latinos are at highest risk. Vision loss can only be prevented by early diagnosis
and treatment. GRF is one of the nation’s few driving forces behind making glaucoma a top national health priority. An
event like Glaucoma 360 raises necessary funds to keep the momentum of this productive research accelerating,
significantly boosts national and international awareness of the immediacy of this cause, and brings together nationally
and internationally respected leaders in medicine, science, business, venture capital, philanthropy, and media.

    4. Wouldn’t investment and research in new treatments and devices for glaucoma happen without GRF and this

                                       Glaucoma Research Foundation Glaucoma 360 FAQs
            Page 1 of 3                                                                               2/13/2012
GRF has been the important “catalyst” for research and continuing investment in glaucoma treatment. GRF has no bias,
no hidden agenda, and no motive other than to help the industry make advancements that ultimately help people
suffering from glaucoma to preserve their vision, and eventually lead to a cure. Everyone involved in glaucoma,
particularly patients, benefits from the work GRF does.
- Through its collaborative research funding program, Catalyst For a Cure, bringing together researchers from
    different universities and laboratories. The synergies and collaboration are bringing results that are an order of
    magnitude better than research from a single lab, university or researcher.
- GRF has funded research leading to treatment therapy advances and advancements in the understanding of
    glaucoma as a neurodegenerative disease, findings that may lead the way to new medications and diagnostic
    devices to detect and treat glaucoma.
- The first large study funded by GRF was the “Normal Tension Glaucoma Study.” The study showed that even in those
    glaucoma cases where eye pressure is in the “normal” range, reducing eye pressure helped manage the disease and
    helped preserve vision.

    5. Who is responsible for this event?

Glaucoma 360 is the inspiration of Dr. Adrienne Graves, PhD and Dr. Andrew Iwach, MD, who are both members of
GRF’s Board of Directors. Dr. Graves is a visual scientist by training, a global industry leader in ophthalmology, and the
former CEO of Santen Inc. Dr. Iwach, GRF’s Board Chair is Executive Director of the Glaucoma Center of San Francisco,
Associate Clinical Professor of Ophthalmology at the University of California at San Francisco, and a faculty instructor at
the California Pacific Medical Center Department of Ophthalmology. The New Horizons Sponsor dinner is co-chaired by
Mona and Ed Zander. The New Horizons Advisory Board includes: Alan S. Crandall, MD, Emmett Cunningham, MD, PhD,
H. Dunbar Hoskins, Jr., MD, Eliot S. Lazar, MD, and Richard L. Lindstrom, MD. See the full list of Advisory Board members.

    6. Will there be a CME for physicians as part of Glaucoma 360?

For the 16th year, GRF hosts the largest certified Continuing Medical Education (CME) meeting dedicated specifically to
the newest information in glaucoma management and treatment. The agenda includes a keynote presentation by
Gregory L. Skuta, MD, President and CEO, Dean McGee Eye Institute, and the Edward L. Gaylord Professor and Chair,
Department of Ophthalmology, University of Oklahoma College of Medicine. Created and directed by Andrew Iwach,
MD, GRF’s Board Chair is Executive Director of the Glaucoma Center of San Francisco, Associate Clinical Professor of
Ophthalmology at the University of California at San Francisco, and a faculty instructor at the California Pacific Medical
Center Department of Ophthalmology. Registration begins at 7:30 am, with the program beginning at 8:00 am,
concluding at 1:00 pm.

    7. Glaucoma 360: Catalyst for a Cure is the annual benefit for Glaucoma Research Foundation. Is this the same
       popular benefit GRF has been hosting for the past six years?

Yes. “Glaucoma 360: Catalyst for a Cure” is GRF’s popular annual benefit, which includes both a silent and live auction
as well as an awards presentation. This year, we are most honored to present our high honors to:
     The Catalyst Award: Richard L. Lindstrom, MD, founder and attending surgeon of Minnesota Eye Consultants
         and Adjunct Professor Emeritus at the University of Minnesota Department of Ophthalmology.
     The President’s Award: Nobuko Saito Cleary, whose leadership has brought GRF’s annual fund-raiser to its
         highest levels of attendance and capacity to develop high net proceeds for GRF initiatives;
     The Visionary Award: Roger McGuinn, co-founder of the band The Byrds and since 2005, Honorary National
         Spokesperson for Glaucoma Research Foundation. Roger will also be performing at the event this year.
     Co-Chairs of this year’s benefit are Nobuko Saito Cleary and Gary Cleary, PharmD, PhD.

                                       Glaucoma Research Foundation Glaucoma 360 FAQs
            Page 2 of 3                                                                               2/13/2012
The annual event includes:
     5 pm: The Innovators’ Circle Reception; by invitation only in appreciation for sponsors and key GRF supporters
       as well as VIP guests at the Innovators ($25,000), Pathfinders ($15,000) and VIP guests.
     6 pm: The President’s Reception, a chance for everyone to meet, connect, and participate in the annual popular
       silent auction
     7 pm: The Dinner and Awards Program.

    8. Tell me a little about Glaucoma Research Foundation.

Founded in San Francisco 33 years ago, Glaucoma Research Foundation (GRF) is America’s oldest and most experienced
institution dedicated solely to its mission: Preventing vision loss from glaucoma by investing in innovative research,
education and support with the ultimate goal of finding a cure. GRF funds results-oriented and innovative research, and
provides educational materials to eye care professionals across the country including the website and
patient education brochures. Research initiatives include the multi-year Catalyst For a Cure (CFC) research consortium
and Shaffer Grants for Innovative Glaucoma Research. 84% of all income received by GRF goes to funding research
projects and patient education and awareness.

    9. I want to be a sponsor. How do I sign up?

All sponsorship proceeds for the three events go directly to benefit GRF.
      To Sponsor New Horizons, and/or Glaucoma Symposium CME: Sponsorships are tailored primarily for the
        business community, especially those seeking ways to express their commitment to the field, demonstrate pre-
        eminent leadership in care and treatment, and achieve highest visibility internationally for their role in making
        possible the event.
      To Sponsor the Benefit: Sponsorships are tailored for individuals, philanthropists and organizations who want to
        contribute to GRF-funded research.
            o Host and Sponsor Benefits are included and outline the visibility for those sponsorships. An early
                commitment qualifies the sponsor for membership on the Benefit Host Committee and visible
                acknowledgment on the benefit invitation, signage at the event, etc.
            o Early donations to our Benefit Auction also qualify you or your organization as a member of the Host
                Committee. More information is listed on the priority reservation form, which can be found here:
      For a sponsorship package, please contact:
            o Carmen Torres at Glaucoma Research Foundation: 415.986.3162 or

    10. What are the media opportunities?

Specifically focused on the medical community, GRF has partnered with Ophthalmology Times as the National Media
Sponsor for Glaucoma 360, and the official publication of Glaucoma 360. “OT” is a physician-driven publication that
disseminates news and information of a clinical, socioeconomic, and political nature in a timely manner for members of
the ophthalmic community.” Partnering with OT assures the widest possible international visibility for the issues raised
during Glaucoma 360.

                                      Glaucoma Research Foundation Glaucoma 360 FAQs
            Page 3 of 3                                                                             2/13/2012

To top